Health Score

0 Excellent

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Attach ORCID iDs across 331 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact331 DOIs

Add abstracts to 248 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact248 DOIs

Deposit reference lists for 83 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact83 DOIs

DOIs for this ISSN

Showing the top 5 of 1032 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	Continued use of MDA-MB-435, a melanoma cell line, as a mode… (10.1038/npjbcancer.2015.2)	Abstract ORCID	82.17	43
2	PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab… (10.1038/s41523-018-0098-y)	Abstract ORCID	71.57	26
3	MONARCH 3 final PFS: a randomized study of abemaciclib as in… (10.1038/s41523-018-0097-z)	ORCID	69.40	596
4	Clinico-pathological factors predicting pathological respons… (10.1038/s41523-025-00729-8)	Abstract ORCID	69.01	23
5	Antibody–drug conjugates in breast cancer: mechanisms of res… (10.1038/s41523-025-00829-5)	Abstract ORCID	68.09	22
6	Quantitative MRI radiomics in the prediction of molecular cl… (10.1038/npjbcancer.2016.12)	ORCID	62.07	303
7	Image analysis with deep learning to predict breast cancer g… (10.1038/s41523-018-0079-1)	ORCID	61.75	294
8	Dynamic HER2-low status among patients with triple negative… (10.1038/s41523-025-00741-y)	Abstract ORCID	61.52	16
9	The WISDOM Study: breaking the deadlock in the breast cancer… (10.1038/s41523-017-0035-5)	ORCID	59.73	244
10	Novel treatment approaches utilizing antibody-drug conjugate… (10.1038/s41523-025-00743-w)	Abstract ORCID	58.80	14
11	Breast cancers are rare diseases—and must be treated as such (10.1038/s41523-017-0013-y)	Abstract ORCID	57.31	13
12	Efficacy of FERscore in predicting sensitivity to ferroptosi… (10.1038/s41523-024-00685-9)	Abstract ORCID	55.70	12
13	Real-World outcomes with sacituzumab govitecan among breast… (10.1038/s41523-025-00736-9)	Abstract ORCID	55.70	12
14	Triple-negative breast cancer: the importance of molecular a… (10.1038/npjbcancer.2016.36)	ORCID	55.50	165
15	Analytical validation of a standardized scoring protocol for… (10.1038/npjbcancer.2016.14)	ORCID	52.60	126
16	Cell state plasticity, stem cells, EMT, and the generation o… (10.1038/s41523-017-0012-z)	ORCID	52.60	126
17	Author Correction: The contribution of pathogenic variants i… (10.1038/s41523-017-0046-2)	References ORCID	52.07	10
18	The untapped potential of radiation and immunotherapy for ho… (10.1038/s41523-025-00796-x)	Abstract ORCID	52.07	10
19	Cyclin E1 and Rb modulation as common events at time of resi… (10.1038/s41523-018-0092-4)	ORCID	51.61	115
20	PARP inhibition in breast cancer: progress made and future h… (10.1038/s41523-022-00411-3)	Abstract	51.52	114
21	The contribution of pathogenic variants in breast cancer sus… (10.1038/s41523-017-0024-8)	ORCID	51.03	109
22	PAM50 gene signatures and breast cancer prognosis with adjuv… (10.1038/npjbcancer.2015.23)	ORCID	49.89	98
23	Randomized phase III trial evaluating the role of weight los… (10.1038/s41523-017-0040-8)	ORCID	47.98	82
24	Author Correction: Evolution of HER2-low expression from pri… (10.1038/s41523-021-00359-w)	Abstract References	47.71	8
25	Personalized mutation tracking in circulating-tumor DNA pred… (10.1038/s41523-025-00778-z)	Abstract ORCID	47.71	8
26	CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity… (10.1038/s41523-025-00851-7)	Abstract ORCID	47.71	8
27	Human brain metastatic stroma attracts breast cancer cells v… (10.1038/s41523-017-0008-8)	ORCID	47.58	79
28	Activin-A signaling promotes epithelial–mesenchymal transiti… (10.1038/npjbcancer.2015.7)	ORCID	47.30	77
29	Dramatic response of metaplastic breast cancer to chemo-immu… (10.1038/s41523-017-0011-0)	ORCID	46.88	74
30	Inflammation of mammary adipose tissue occurs in overweight… (10.1038/s41523-017-0015-9)	ORCID	46.43	71
31	Clinical outcomes in ER+ HER2 -node-positive breast cancer p… (10.1038/s41523-017-0033-7)	ORCID	46.43	71
32	MiR-221/222 promote epithelial-mesenchymal transition by tar… (10.1038/s41523-018-0073-7)	ORCID	45.97	68
33	Patterns of cell cycle checkpoint deregulation associated wi… (10.1038/s41523-017-0009-7)	ORCID	45.32	64
34	Heterocellular gene signatures reveal luminal-A breast cance… (10.1038/s41523-019-0116-8)	ORCID	45.15	63
35	Author Correction: Clinical, pathological, and PAM50 gene ex… (10.1038/s41523-023-00538-x)	Abstract References	45.15	7
36	Temporal evolution of breast cancer brain metastases treatme… (10.1038/s41523-025-00735-w)	Abstract ORCID	45.15	7
37	Body composition metrics as a determinant of trastuzumab der… (10.1038/s41523-025-00754-7)	Abstract ORCID	45.15	7
38	Breast cancer risk factors and mammographic density among hi… (10.1038/s41523-018-0055-9)	ORCID	44.98	62
39	Clinical outcomes in patients with node-negative breast canc… (10.1038/s41523-017-0034-6)	ORCID	43.70	55
40	Somatic mutations in leukocytes infiltrating primary breast… (10.1038/npjbcancer.2015.5)	ORCID	43.51	54
41	AXL-associated tumor inflammation as a poor prognostic signa… (10.1038/npjbcancer.2016.33)	ORCID	43.51	54
42	Therapeutic targeting of BRCA1 and TP53 mutant breast cancer… (10.1038/s41523-019-0110-1)	ORCID	43.51	54
43	A metastasis biomarker (MetaSite Breast™ Score) is associate… (10.1038/s41523-017-0043-5)	ORCID	43.11	52
44	Prognostic characteristics in hormone receptor-positive adva… (10.1038/s41523-018-0094-2)	ORCID	43.11	52
45	Dual PI3K and Wnt pathway inhibition is a synergistic combin… (10.1038/s41523-017-0016-8)	ORCID	42.90	51
46	A functional genomic screen in vivo identifies CEACAM5 as a… (10.1038/s41523-018-0062-x)	ORCID	42.90	51
47	Association of B7-H4, PD-L1, and tumor infiltrating lymphocy… (10.1038/s41523-018-0095-1)	ORCID	42.90	51
48	A perspective on the development and lack of interchangeabil… (10.1038/s41523-022-00451-9)	Abstract	42.90	51
49	Breast cancer cell adhesome and degradome interact to drive… (10.1038/npjbcancer.2015.17)	ORCID	42.69	50
50	Relationships between pathology and crystal structure in bre… (10.1038/npjbcancer.2016.29)	ORCID	42.03	47